Q-omics provides the consensus-scored CTNNBIP1 profile across patient tissues and cancer cell-line models. CTNNBIP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CTNNBIP1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CTNNBIP1 protein abundance shows 19,917 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KICH, and BRCA as cancer lineages where CTNNBIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTNNBIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTNNBIP1 survival associations across molecular data types. CTNNBIP1 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTNNBIP1 RNA expression–survival associations across cancer types. High CTNNBIP1 expression shows unfavorable associations in ACC and PAAD, but favorable associations in UVM, UCEC, KIRP and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CTNNBIP1 RNA expression.
This table summarizes CTNNBIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CTNNBIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTNNBIP1 shows lower tumor expression in KICH, KIRC and LUAD and higher tumor expression in COAD, LIHC and BLCA. The KICH box plot shows higher CTNNBIP1 RNA expression in normal versus tumor tissue (log2 FC = −1.612, t-test p < 0.001).
This table shows molecular features associated with CTNNBIP1 in patient tissues and cancer cell lines. In patient samples, CTNNBIP1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CTNNBIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
